This week's biopharma funding and startup activity includes some significant milestones. Newly launched company from Univ. of Hawaii, Komo Biosciences raised funds to advance the gene editing field with integrase technology. Spotlight Medical, secured a total of $6.2M in Seed funding a month after emerging from stealth to enhance cancer treatment with AI.
Want to get this list of recently funded companies and more data? Fill out a quote request to get more info (Quote Request Form).
FIG. 1. Recent Biotech Funding Activity.
– Private Funding –
Komo Biosciences
💸 Launched with funding from Genesis BioCapital and other investors to advance gene editing technology using integrase technology.
Spotlight Medical
💸 Raised €6.2M in Seed funding a month after emerging from stealth to enhance cancer treatment with AI.
Element Biosciences
💸 Raised $277M in Series D funding led by Wellington Management to support commercialization of benchtop DNA sequencer.
SciRhom
💸 Received €64M series A funding to be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.
AusperBio
💸 Secured $37M in Series A financing led by InnoPinnacle Fund to support the development of AHB-137 for HBV.
– Post-IPO/Public Funding –
Alvotech
🏦 Closed $965M private debt financing to continue advancing the development pipeline.
IDEAYA Biosciences
🏦 Announced pricing of $263M public offering.
Moderna
🏦 Received a $176M grant from BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate the Development of an mRNA-based Pandemic Influenza Vaccine.
Cartesian Therapeutics
🏦 Secured $130M in financing for its pipeline programs and general corporate purposes.
BioNano Genomics
🏦 Announced a $30M public offering with $10M upfront and an additional $20M upon exercise of clinical milestone-linked warrants.
---
Article History:
RF, EV, DG (07/17/24)
This article is not investment or legal advice.
Comments